No significant differences between dual-chamber and single-chamber (ventricular or atrial) pacemakers were identified for major outcomes, such as mortality and stroke, in patients with sick sinus syndrome and/or atrioventricular block. The authors' conclusion that there are small, but potentially important, benefits associated with dual-chamber compared with ventricular pacing, is broadly supported by the data, but significant areas of uncertainty remain.
The methodological quality of included RCTs was assessed using criteria published in the Centre for Reviews and Dissemination (CRD) Report No. 4, which assess the potential for selection bias, performance bias, detection bias and attrition bias.
The authors did not describe the process of quality assessment, or how many reviewers were involved.
Data extraction
Raw data were extracted from included studies where possible, otherwise summary measures were extracted as reported. The summary effect measures used in the review were odds ratio (OR) for dichotomous outcomes (e.g. mortality, stroke), standard mean difference (SMD) for continuous outcomes (e.g. exercise capacity, symptom scores) and risk difference (RD) for incidence of pacemaker syndrome.
Data were extracted by one reviewer, using a project-specific, piloted data extraction sheet, and checked by a second.
Methods of synthesis
The results of included studies were summarised, in text and tables, stratified by study type (parallel or cross-over RCT), comparator (ventricular or atrial single-chamber pacing) and outcome measure. Where sufficient data were available, the results of individual trials were pooled using random-effects meta-analyses. Between study heterogeneity was assessed using the I 2 statistic.
Results of the review
Thirty four RCTs were included in the review, five parallel (n=7,183) and 29 cross-over (n=524). The quality of the parallel trials was generally reasonable, including large numbers of participants and running over three to five years. Individual quality criteria were discussed in full in the report, in relation to each included study. Cross-over trials were generally much smaller and of shorter duration. A wider range of outcomes were assessed but short duration precluded the assessment of outcomes such as mortality.
Dual-chamber versus single-chamber ventricular pacing:
Dual chamber pacing was not associated with significant improvement in mortality, stroke, heart failure, or functional capacity measured by specific activity scale.
Dual chamber pacing significantly reduced the incidence of atrial fibrillation, pooled OR 0.76 (95% CI: 0.65, 0.90, p=0.001, three parallel RCTs). Dual chamber pacing significantly improved exercise capacity, SMD 0.35 (95% CI: 0.17, 0.52, p<0.0001, 20 crossover RCTs). No differences were found in exercise capacity by age.
Quality of life was assessed in 17 trials (four parallel and 13 cross-over) using a wide range of instruments. Results were variable with some evidence of improvement associated with dual-chamber pacing, mostly from cross-over studies. Three parallel trials used Short Form 36 to assess quality of life. One trial found significant improvements associated with dual-chamber pacing in some components (physical function, physical role, social function, energy, mental health and pain) at 48 month follow-up. Twelve cross-over studies measured general well-being in a variety of ways and found improvements associated with dual-chamber-pacing, SMD 1.59 (95% CI: 0.95, 2.23, p<0.00001), but significant between study heterogeneity (I 2 83.6%).
The incidence of pacemaker syndrome varied between 4% (inferred) and 26%. Dual-chamber pacing significantly relieved the symptoms of pacemaker syndrome when these occurred and pacemaker syndrome was an major reason for cross-over in the parallel trials. The majority of complications were perioperative. Dual chamber pacing was associated with higher rates of lead dislodgement (4.2% versus 1.4%) and inadequate pacing (1.3% versus 0.3%). Other complication rates were similar. Subgroup analyses from the large parallel trials showed no evidence of differential effects of dual-pacing in identifiable patient groups.
Dual-chamber versus single-chamber atrial pacing: No significant differences were found in mortality, stroke, heart failure, overall exercise capacity, functional status, or quality of life.
